Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Goldenwell BiotechGWLL 30 EV-to-EBIT is -332.77 as of Jul. 29, 2026. GuruFocus rates GWLL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,559 Consumer Packaged Goods companies, Goldenwell Biotech ranks worse than 64143.62% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Goldenwell Biotech's Enterprise Value for the quarter that ended in Mar. 2026 was $99.43 Mil.
Goldenwell Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Goldenwell Biotech EV-to-EBIT Related Terms
Goldenwell Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Goldenwell Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Goldenwell Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Goldenwell Biotech EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Goldenwell Biotech's EV-to-EBIT falls into.
Goldenwell Biotech's current Enterprise Value is $89.18 Mil.
Goldenwell Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Goldenwell Biotech (GWLL) has a EV-to-EBIT of -332.77 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Goldenwell Biotech and its competitors. According to the industry distribution chart, Goldenwell Biotech ranks #999999 out of 1559 companies in the Consumer Packaged Goods industry.
Is Goldenwell Biotech's EV-to-EBIT too high?
Goldenwell Biotech's current EV-to-EBIT is -332.77. Based on the distribution chart, Goldenwell Biotech ranks #999999 out of 1559 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Goldenwell Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Goldenwell Biotech's EV-to-EBIT compare to LFVN and FTLF?
According to the Consumer Packaged Goods industry distribution chart, Goldenwell Biotech ranks #999999 out of 1559 companies for EV-to-EBIT. This places Goldenwell Biotech in the lower half of its industry. The industry median EV-to-EBIT is 11.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 11.93, based on 1,559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Goldenwell Biotech and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 11.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Goldenwell Biotech's current EV-to-EBIT is -332.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Goldenwell Biotech stock overvalued right now?
Goldenwell Biotech (GWLL) has a current EV-to-EBIT of -332.77. The current EV-to-EBIT is -332.77. Goldenwell Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Goldenwell Biotech (GWLL), the current EV-to-EBIT is -332.77 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Goldenwell Biotech Inc is engaged in the research and development, production, and sales of healthcare and supplement products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
30GF Score
Get the complete analysis for GWLL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GWLL has been successfully added to your 
